SETD2 and central nervous system cancer: SETD2-inactivating mutations are also observed in different types of cancers, including in the CNS tumours [17,26] which are most predominantly found in paediatric and young adult high-grade gliomas located in the cerebral hemispheres and lead to 15%–28% and 8% of paediatric and adult high-grade gliomas respectively (figure 2) [26].